Can scientists predict which cancer markers are likely to trigger an immune response?

September 12, 2019

Scientists at the University of North Carolina Lineberger Comprehensive Cancer Center have designed and validated a model for predicting what might make an effective cancer vaccine against a patient’s tumor. This finding could help overcome a significant obstacle in the development of personalized cancer vaccines. In a study published in the journal Cancer Immunology Research, … Continued

Ting elected vice president of the American Association of Immunologists

June 3, 2019

Jenny P. Ting, PhD, the William Kenan Professor of Genetics and Microbiology & Immunology has been elected to serve as vice president of the American Association of Immunologists for the 2019-2020 term. Ting has been an active member of the organization for since 1997. AAI is dedicated to advancing the field of immunology and fostering … Continued

Researchers study strategies for using nanotechnology to boost cancer therapeutics

April 11, 2019

University of North Carolina Lineberger Comprehensive Cancer Center researchers presented innovative new strategies for using tiny particles – particles the size of a DNA molecule or the width of a human hair – to boost cancer treatment as part of the Carolina Center of Cancer Nanotechnology Excellence/National Cancer Institute site visit on Tuesday. The researchers, … Continued

Wang and Serody awarded $2M grant to study personalized cancer vaccines

December 3, 2018

The University of North Carolina System recently awarded UNC Lineberger’s Andrew Wang, MD, and Jonathan Serody, MD, a four year, $2.09 million Research Opportunities Initiative grant to support their research using pharmacoengineering approaches to develop more effective personalized cancer vaccines. The grant was one of 15 awarded to scientists across the UNC System, with the specific intent to support … Continued

Viral protein helps drive cancer, study shows

May 9, 2018

UNC Lineberger researchers led by Blossom Damania, PhD, and Penny Anders, PhD, published a paper in the Journal of Clinical Investigation that explains how the viral protein vPK helps drive abnormal growth of immune cells called B cells. Their findings identify vPK as a potential druggable target to block or treat cancer in people infected with the virus.